---
title: "Palisade Bio, Inc. (PALI.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/PALI.US.md"
symbol: "PALI.US"
name: "Palisade Bio, Inc."
industry: "生物技术"
---

# Palisade Bio, Inc. (PALI.US)

| Item | Detail |
|------|--------|
| Industry | 生物技术 |
| Location | 美股市场 |
| Website | [www.palisadebio.com](https://www.palisadebio.com) |

## Company Profile

Palisade Bio, Inc.是一家临床阶段的生物制药公司，专注于为患有自身免疫、炎症和纤维化疾病的患者开发和推进新型治疗药物。该公司的主要治疗候选药物是 PALI-2108，一种前药 PDE4 抑制剂，目前正在进行针对溃疡性结肠炎的 1a/b 期临床试验，以及针对纤维狭窄型克罗恩病的 1a 期临床试验。公司与 Giiant Pharma, Inc.签订了研究合作和许可协议，以开发、生产和商业化其化合物；与加利福尼亚大学校董会签订了许可协议，专门用于维持 Newsoara 的共同开发；并与 Newsoara Biopharma Co., Ltd.签订了共同开发和分销协议

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -22.43 | 511/603 | - | - | - |
| PB | 78.45 | 434/603 | 83.55 | 2.03 | 0.45 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-03T05:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 3 | 60% |
| Overweight | 2 | 40% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.64 |
| Highest Target | 25.00 |
| Lowest Target | 6.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/PALI.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/PALI.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/PALI.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.